// App-Quantinova.ai

P284 : Certolizumab pegol-treated patients with non-radiographic axSpA demonstrate improvements in sleep quality and other patient reported outcomes

Researchers

Presenter

  • Raj Sengupta

Principal Investigators

  • Lianne Gensler

  • Jonathan Kay

  • Walter Maksymowych

  • Nigil Haroon

  • Lars Bauer

  • Bengt Hoepken

  • Natasha de Peyrecave

  • Thomas Kumke

  • Atul Deodhar

Medical Centers

  • Rheumatology, The Royal National Hospital for Rheumatic Diseases, Bath, UNITED KINGDOM

  • Rheumatology, University of CA San Francisco, San Francisco, CA

  • Division of Rheumatology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA

  • Department of Internal Medicine, University of Alberta, Edmonton, AB, Canada

  • Rheumatology, University Health Network, Krembil Research Institute, and University of Toronto, Toronto, ON, CANADA

  • Immunology, UCB Pharma, Monheim, GERMANY

  • Immunology, UCB Pharma, Brussels, BELGIUM

  • Pediatrics, Oregon Health & Science University, Portland, OR

Locations

  • United Kingdom

  • United States

  • Canada

  • Germany

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • C reactive protein

  • Nutritional risk screening

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02552212

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved